SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin plans to launch around 25 products in US in FY17

16 Aug 2016 Evaluate

Drug major Lupin is planning to launch around 25 products in the US market in FY17. Apart from the Gavis portfolio, Fortamet and Glumetza, the company is expecting to launch products like Minastrin and Epzicom. The Mumbai-based firm is planning to go ahead with launches on the dermatology front this year.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2249.70 -128.20 (-5.39%)
11-May-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1282.15
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2249.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×